T he treatment strategy for Crohn's disease (CD) has changed considerably since the introduction of anti-tumor necrosis factor (TNF)-a agents, which have been shown to provide remarkable efficacy for the induction and maintenance of remission and improvement of long-term prognosis. However, primary nonresponders and patients with loss of response because of a low concentration of anti-TNF-a agents or antibiologic antibody formation against anti-TNF-a agents have been reported. The annual rate of loss of response to anti-TNF-a agents has been estimated at approximately 13%. 1, 2 In the SONIC trial, Colombel et al 3 demonstrated that combination therapy with infliximab, a chimeric immunoglobulin G1 monoclonal antibody against anti-TNF-a, and azathioprine was more efficacious than monotherapy with either medication alone for the maintenance of remission in CD. In that trial, a combination with azathioprine was efficacious for the prevention of antibiologic antibody formation. The trial also showed that therapeutic drug monitoring for the serum trough level of infliximab and antibiologic antibodies was necessary for the optimization of CD treatment. 1 Recently, we reported the results of a prospective, multicenter randomized controlled trial (DIAMOND trial) that compared the clinical efficacy of adalimumab (ADA) monotherapy with a combination of ADA and azathioprine in patients with moderate to severe active CD who were naive to biologics and immunomodulators. 4 The DIAMOND trial revealed that the remission rates at Weeks 26 and 52 were similar between the monotherapy and combination groups. 5 Colonoscopic monitoring is one of the procedures required for the optimization of CD treatment, because mucosal healing (MH), as determined by conventional ileocolonoscopy, is the ideal therapeutic goal in clinical practice. 6 In this subanalysis of data obtained from the DIAMOND trial, we aimed to evaluate the contribution of azathioprine and therapeutic drug monitoring to endoscopic response (ER) and MH, along with other clinical factors associated with those outcomes, in patients with CD treated with ADA.
Materials and Methods

Patients
We analyzed the data from the DIAMOND trial (UMIN registration No. 000005146); the methods used in this trial have been reported in detail. 4 Briefly, the enrolled patients had moderate-to-severe active CD, were naive to anti-TNF-a agents and immunomodulators, had received a definitive diagnosis of CD at least 3 months prior, and were aged between 15 and 65 years.
Moderate-to-severe CD was defined as disease with a CD activity index (CDAI) !220.
7 Each patient was treated with subcutaneous administrations of ADA at a dose of 160 mg at Week 0, a dose of 80 mg at Week 2, and 40 mg for every other week thereafter up to 52 weeks. Patients who were assigned to a combination of ADA and azathioprine (combination group) were further treated with oral administration of azathioprine during the investigation period, whereas those assigned to monotherapy with ADA (monotherapy group) were not administered azathioprine. Patients in the combination group were initially treated with 25 mg or 50 mg/day of azathioprine, and a dose increase up to a maximum of 100 mg was allowed during the initial 4 weeks under careful observation. The maximal dose of azathioprine was chosen in consideration of 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. 8 Follow-up data were collected several weeks after each patient completed the study at Week 52 or immediately after withdrawal from the clinical trial.
The protocol of the clinical trial was approved by the institutional review board at each participating institution, and informed consent to participate in the study was obtained from each participant before enrolment. All authors had access to the study data and had reviewed and approved the final manuscript.
Clinical and Endoscopic Efficacy
We assessed demographic data including, age, sex, body weight, body mass index, duration of disease, disease location, past history of surgery, presence of internal fistula and per anal fistula, smoking status, any simultaneous treatment, and serum C-reactive protein (CRP) level.
CDAI scores were determined at Weeks 0, 2, 4, 12, 26, and 52. Conventional ileocolonoscopy was performed at baseline, Week 26, and Week 52. At each colonoscopy, mucosal lesions were assessed based on the simple endoscopic score for CD (SES-CD). 9 Clinical remission was defined as a CDAI score less than 150 points. 8 Clinical response was defined as reduction in CDAI from the baseline value by more than 70 points. ER at Week 26 and Week 52 was defined as a decrease of SES-CD by at least 8 points from baseline or SES-CD 4.
10 MH at Week 26 and Week 52 was defined as SES-CD 2.
11
All research collaborators were actually IBD experts and had competent experiences for reading and scoring of SES-CD.
Therapeutic Drug Monitoring Approach
We collected serum samples from patients in both groups at Week 26 and measured trough levels of ADA using enzyme-linked immunosorbent assay (Sanquin, Amsterdam, the Netherlands) based on the principle that ADA is captured via its ability to bind TNF-a. The assay detection limit is approximately 0.001 mg/L. 12 
Statistical Analysis
Analyses of ER and MH included all patients randomly assigned to the monotherapy or combination groups according to the intention-to-treat principle, with nonresponder imputation for missing data caused by withdrawal, dropout, or any other reason. Among withdrawal and dropout cases, exacerbation of CD was classified as endoscopically unimproved, and withdrawal cases were excluded from the analysis. For endoscopic improvement and MH, Fisher exact test was used to test independence between groups, and odds ratios (ORs) and their confidence intervals (CIs) were calculated using a logistic regression model. Multiple logistic regression analysis was used to estimate the OR after adjustment for potential confounders and to identify factors independently associated with ER and MH at Weeks 26 and 52. Covariates included in the model were age, sex, body weight, body mass index, duration of the disease, disease location, previous surgery, presence of internal fistula, presence of anal fistula, smoking status, medication, CDAI, CRP at trial entry, combination or monotherapy group, achieving remission at Week 12, and ADA trough level at Week 26. For the multivariate analysis, the backward elimination method was used (variables were eliminated when Wald P > .1, but stopped elimination when the number of covariates was 4) after including these covariates because of limited outcome numbers. Student t test was used to examine the association between ER or MH and ADA trough level. ADA trough value was categorized into quartiles for categorical analysis. The P for trend was calculated using the chi-square test for linear trends or by including categorized values in the logistic models as numerical values. ADA trough level was added to the logistic models with factors selected by the previously mentioned method to assess its association with the outcomes after adjustment for potential prognostic factors. The dose-response relationship between ADA trough level and the achievement of the outcomes was summarized in graphs using crude and mean adjusted probabilities estimated by the logistic models. Each variable of the SES-CD was compared using the paired Student t test. Analyses were performed using SPSS Statistics software version 23 (IBM, Armonk, NY). P values <.05 were considered statistically significant for all analyses.
Results
Study Population
In the DIAMOND trial, 176 patients were randomly assigned to either ADA monotherapy (n ¼ 85) or ADA in combination with azathioprine (n ¼ 91). SES-CD data were available for 149 patients at Week 26 (monotherapy group, n ¼ 69; combination group, n ¼ 80) and for 154 patients at Week 52 (monotherapy group, n ¼ 75; combination group, n ¼ 79) from 44 referral sites. Among 41 patients with adverse events, 26 patients who withdrew from the trial because of worsening of CD were regarded as endoscopic nonresponders (nonresponder imputation), whereas 15 patients who discontinued the study drug were excluded from the analysis (Figure 1 ). In excluded patients, 4 patients were leukopenia, 3 were alopecia, 2 were liver damage, and each of nausea, fever, appendicitis, hyperamylasemia, lymphadenopathy in the combination group, and 1 patient with aortitis in the monotherapy group. Ultimately, 135 patients (monotherapy group, n ¼ 68; combination group, n ¼ 67) at Week 26 and 139 patients (monotherapy group, n ¼ 74; combination group, n ¼ 65) at Week 52 were analyzed for the present investigation. There was no statistical difference for baseline SES-CD scores at Week 0 between monotherapy group (15.7 AE 7.5) and combination group (14.2 AE 7.9) (P ¼ .217). In case of moderate or severe endoscopic active cases (SES-CD !7), there was also difference between monotherapy group (n ¼ 77) and combination group (n ¼ 65) (P ¼ .317).
Comparison of Endoscopic Response and Mucosal Healing Between Adalimumab Monotherapy and Combination Groups
The ER rate at Week 26 was significantly higher in the combination group (71.6%) than in the monotherapy group (54.4%) (OR, 2.12; 95% CI, 1.04-4.32; P ¼ .050), whereas the rate at Week 52 did not significantly differ between the combination group (60.0%) and the monotherapy group (50.0%) (OR, 1.50; 95% CI, 0.77-2.94; P ¼ .306) (Figure 2 ). The MH rate was not significantly different between the 2 groups at Week 26 (combination group, 20.9%; monotherapy group, 10.3%; OR, 2.30; 95% CI, 0.87-6.13; P ¼ .102) or at Week 52 (combination group, 21.5%; monotherapy group, 12.2%; OR, 1.98; 95% CI, 0.80-4.95; P ¼ .172), although there was a trend toward a higher MH rate in the combination group.
As shown in the forest plot comparing ER and MH between the 2 groups ( Supplementary Figure 1) , combination therapy resulted in higher ER rate at Week 26.
Factors Associated With Endoscopic Response and Mucosal Healing
Univariate analysis revealed that combination therapy (OR, 2.12; 95% CI, 1.04-4.32; P ¼ .040) and higher ADA trough level at Week 26 (OR, 1.34 per 1 mg/mL increase; 95% CI, 1.17-1.53; P < .001) were associated with ER at Week 26. Higher ADA trough level at Week 26 (OR, 1.25 per 1 mg/mL increase; 95% CI, 1.12-1.40; P < .001) was also associated with ER at Week 52. Higher CRP at Week 0 (OR, 1.14; 95% CI, 0.99-1.31; P ¼ .069), higher CDAI at Week 0 (OR, 1.01; 95% CI, 0.999-1.01; P ¼ .075), shorter duration of disease (OR, 0.99; 95% CI, 0.99-1.001; P ¼ .078), and enteral nutrition intake (!900 kcal/day; OR, 0.48; 95% CI, 0.21-1.10; P ¼ .085) tended to be associated with ER at Week 52 (all ORs correspond to a 1-unit increase). In the multivariate analysis, higher ADA trough level at Week 26 (OR, 1.30 per 1 mg/mL increase; 95% CI, 1.13-1.51; P < .001) and shorter disease duration (OR, 0.99 per month increase; 95% CI, 0. As shown in Table 1 , multivariate analyses identified CDAI at Week 0 (OR, 1.01 per 1 score increase; 95% CI, 1.000-1.02; P ¼ .047), SES-CD score at Week 0 (OR, 0.80 per 1 score increase; 95% CI, 0.72-0.90; P < .001), and (Figure 3 ). Similarly, the trough level was significantly higher in patients with ER at Week 52 than in those without (8.16 AE 3.68 vs 5.35 AE 3.38 mg/mL; P < .001).
Meanwhile, the trough level was significantly higher in patients with MH at Week 52 than in those without (9.99 AE 3.51 vs 6.37 AE 3.57 mg/mL; P < .001), although the difference in trough level was not significant between patients with and without MH at Week 26 (8.29 AE 3.56 vs 6.94 AE 3.74 mg/mL; P ¼ .131).
The dose-response relationships between quartile of ADA trough level at Week 26 and rates of ER and MH achievement at Weeks 26 or 52 were assessed using crude and adjusted mean probability of the outcomes estimated by the previous logistic regression models (Figure 4 ). Except for MH at Week 26 (P for trend <.280), all outcomes were significantly correlated with ADA trough level (ER at Week 26; P for trend <.001). In other words, higher ADA trough level at Week 26 was associated with achievement of ER and MH at Week 52 (ER: P for trend <.001; MH: P for trend ¼.001).
Changes in Simple Endoscopic Score for Crohn's Disease Variables
Among the 4 variables included in the SES-CD (size of ulcers, ulcerated surface, affected surface, and presence of narrowing), the score for narrowing remained unchanged after ADA administration, whereas some of other variables improved significantly compared with the changing of the score for narrowing at Week 26 (P ¼ .002 for size of ulcers; P ¼ .001 for ulcerated surface) or at Week 52 (P ¼ .049 for ulcerated surface). The changes in each variable did not differ between the monotherapy and combination groups.
Discussion
To date, DIAMOND is the only investigation to prospectively compare ER and MH between patients treated by ADA monotherapy and those treated by a combination of ADA and immunomodulators. In the present subanalysis of the data obtained in the DIAMOND trial, ER rate, defined as a decrease in SES-CD from baseline by at least 8 points or SES-CD 4, was significantly higher in the combination group than in the monotherapy group at Week 26, but not at Week 52, whereas the rate of MH, defined as SES-CD 2, did not differ between the 2 groups at either Week 26 or Week 52. Interestingly, multivariate analyses also revealed that higher CDAI and lower SES-CD score were associated with a higher rate of MH at Weeks 26 and 52.
The ER and MH data used in the present subanalysis are not the same as those reported in our prior report on the DIAMOND trial (84.2% in the combination group vs 63.8% in the monotherapy group at Week 26, P ¼ .019; 79.6% vs 69.8% at Week 52, P ¼ .36). 4 As in the SONIC trial 3 the statistical analysis in our original report was performed based on the intention-to-treat principle. However, we applied nonresponder imputation in the present subanalyses for the purpose of comparing actual MH between subjects treated by ADA monotherapy and in combination with azathioprine. We thus regarded 26 patients who withdrew from the trial because of worsening of CD as nonresponders based on colonoscopy.
In the post hoc analysis of the SONIC trial that enrolled patients with available CDAI, CRP, and endoscopic data, the rate of MH at Week 26, defined as the absence of any mucosal ulcers (including aphthoid ulcers), was significantly higher in the combination group (65.3%) than in monotherapy groups treated with either infliximab (43.6%; P ¼ .015) or azathioprine alone (29.6%; P < .001). 13 The difference in pharmacokinetics between infliximab and ADA is one of the suggested explanations for the difference in the efficacy of azathioprine in the induction of MH between the SONIC and DIAMOND trials. In the SONIC trial, serum infliximab trough level was significantly higher in the combination therapy group (3.5 mg/mL) than in the infliximab monotherapy group (1.6 mg/mL) at Week 30 (P < .001). 3 In the DIAMOND trial, however, the ADA trough level was not statistically different between the monotherapy group (6.5 mg/mL) and the combination group (7.6 mg/mL) (P ¼ .084). Another possible explanation for the difference between the SONIC and DIAMOND trials is the difference in the definition used for MH. In the SONIC trial, MH was defined as the absence of any mucosal ulcers (including aphthoid ulcers). Thus, cases with diffuse erosions or stricture were regarded as having MH in the SONIC trial.
As recently suggested in the IOIBD technical review, 11 our definition of MH (SES-CD 2) in the present subanalysis seems to be more practical. The present analysis identified higher CDAI and lower SES-CD score at Week 0 and shorter duration of disease as factors associated with MH at Week 26. Higher CDAI and lower SES-CD score at Week 0 were also closely associated with MH at Week 52. The contribution of low SES-CD to MH can be presumably explained by the definition of MH (SES-CD 2), because patients with low SES-CD are rational candidates for MH after therapy. 14 The contribution of shorter duration of CD to MH also seems consistent with the results of prior investigations showing the clinical efficacy of ADA in patients with CD. 15, 16 However, we are unable to conclude that patients with clinically active CD are candidates for MH with ADA treatment, because we did not evaluate small bowel lesions of the entire small bowel in our subjects. The higher CDAI found in the present study may be a consequence of ileal lesions in the proximal small bowel of terminal ileum and complications, which are in fact unrelated to the response of colonic lesions to ADA. 17, 18 Interestingly, the ADA trough level was significantly higher in patients who achieved ER than in those without ER both at Week 26 and 52. The ADA trough level was also significantly higher in patients with MH than in those without MH at Week 52. Additionally, higher ADA trough level at Week 26 was associated with achievement of ER and MH at Week 52. As reported previously, the combination group demonstrated trends toward higher ADA trough level and lower rate of anti-ADA antibody positivity compared with the monotherapy group in the DIAMOND trial. 4 Therefore, the combination of ADA and azathioprine seems to improve ER via azathioprine-induced changes in the pharmacokinetics of ADA. 19 SES-CD includes 4 variables: (1) size of ulcers, (2) ulcerated surface, (3) affected surface, and (4) presence of narrowing. Among these 4 variables, narrowing improved less frequently in our subjects, as compared with the other 3 variables at Weeks 26 and 52, and this trend was observed irrespective of the use of azathioprine. These results suggest that, regardless of azathioprine therapy, an accelerated step-up approach with objective monitoring for the prevention of narrowing may provide better outcomes in patients treated by ADA. 20 There were some limitations to this subanalysis. First, the scorings of SES-CD were not performed in a central reading manner. However, our research collaborators were specialists for both of CD management and endoscopic examination. Therefore, we believe that there are not significant interobserver variations among the data for SES-CD. Second, the number of subjects analyzed for the present investigation may not be sufficient, because we used data collected from a sample size calculated for the preceding DIAMOND trial, and because SES-CD and ADA trough level were missing in some of the participants in the DIAMOND trial.
In conclusion, this report, to our knowledge, is the first to reveal that combination therapy increases trough levels and higher trough levels are associated with ER and MH in a prospective randomized fashion. Higher ADA trough level at Week 26 was associated with better endoscopic improvement, ER and MH, at Week 52. For patients with CD treated with ADA, the use of azathioprine as an adjuvant should be optimized based on clinical course and endoscopic findings, especially with respect to narrowing.
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